7/18/2019  8:05:57 AM Chg. -2.30 Volume Bid4:53:54 PM Ask4:53:54 PM Market Capitalization Dividend Y. P/E Ratio
203.15EUR -1.12% 2
Turnover: 406.30
205.50Bid Size: 100 206.00Ask Size: 100 39.64 bill.EUR - -

Business description

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
 

Management board & Supervisory board

CEO
Michel Vounatsos
Management board
Jeffrey D. Capello, Chirfi Guindo, Daniel Karp, Dr. Alfred W. Sandrock Jr., Dr. Ginger Gregory, Dr. Michael Ehlers, Susan H. Alexander
Supervisory board
Dr. Stelios Papadopoulos, Brian S. Posner, Caroline Dorsa, Dr. Alexander J. Denner, Dr. Richard C. Mulligan, Eric K. Rowinsky, Michel Vounatsos, Nancy L. Leaming, Robert W. Pangia, Stephen A. Sherwin, The Honorable Lynn Schenk
 

Company data

Name: Biogen Inc.
Address: 225 Binney Street,Cambridge, Massachusetts 02142, USA
Phone: +1-671-679-2000
Fax: +1-617-679-2617
E-mail: -
Internet: www.biogen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 77.83%
IPO date: -

Investor relations

Name: Matt Calistri
IR phone: +1-781-464-2442
IR Fax: -
IR e-mail: IR@biogenidec.com

Company calendar

CW 30 | 7/23/2019 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Freefloat
 
77.83%
BlackRock, Inc.
 
7.96%
PRIMECAP Management Company
 
7.16%
The Vanguard Group
 
7.05%
Others
 
0.00%